| Continued expansion of digitally native brands into physical retail and wholesale partnerships, with key updates from companies like Lulus and Purple. This includes new store openings, expanded wholesale agreements, and reporting on the financial impact of these omnichannel strategies. | Ongoing through 2027 | 2026-11-07 | 2027-12-31 | This trend is central to the theme's evolution, as DTC brands seek to expand customer reach beyond purely digital channels. Success in omnichannel strategies can improve product discovery, conversion, and brand building, but also introduces risks like increased operating costs and channel conflict, impacting the unit economics of multiple theme members. | Theme | theme_composer | LVLU, PRPL, WRBY, LOVE, GROV | 5 | 0.0131 | 1.18 | 0.85 | | 1.0 | 1.3129 | 2026-11-07 | False | 1 | 0.9158 | 91.8544 | theme_composer | Theme composer | | |
| Resolution or significant update on the FTC complaint against Hims & Hers regarding deceptive billing, difficult cancellations, and improper data sharing. The outcome could impact operational practices and regulatory compliance for DTC subscription models. | Ongoing, potentially Q4 2026 or H1 2027 | 2026-11-07 | 2027-06-30 | This catalyst carries significant regulatory and financial risk for Hims & Hers, potentially leading to fines or mandated operational changes. More broadly, the resolution could set precedents for consumer protection, billing practices, and data privacy within the DTC subscription and digital health sectors, affecting other theme members with similar business models. | Theme | theme_composer | HIMS, BARK, GROV | 3 | 4.515 | 1.18 | 0.92 | Regulatory/Policy | 1.35 | 661.7007 | 2026-11-07 | False | 1 | 0.5162 | 75.6593 | theme_composer | Theme composer | | |
| FDA provides 'full and final rule making' on peptide therapies, clarifying regulatory pathways for digital health platforms. This decision will determine the scope and speed at which companies like Hims & Hers can expand their offerings in this high-growth category. | Q4 2026 | 2026-11-07 | 2026-12-31 | This catalyst is critical for Hims & Hers, as it would validate its verticalized peptide strategy and unlock a significant growth market. A favorable ruling could also set a precedent for other digital health platforms looking to enter or expand in complex therapeutic areas, influencing the broader DTC health landscape. | Theme | theme_composer | HIMS | 1 | 4.35 | 1.18 | 1.0 | Regulatory/Policy, Court/Legal, Conference/Council | 2.106 | 1081.0098 | 2026-11-07 | False | 1 | 0.0012 | 0.306 | theme_composer | Theme composer | | |
| Hims & Hers launches already allowed peptide therapies (sermorelin, glutathione, NAD+). This launch will demonstrate the company's ability to execute on its verticalized strategy and capitalize on the growing demand for longevity and wellness treatments. | Q4 2026 | 2026-11-07 | 2026-12-31 | For Hims & Hers, this launch represents a tangible step in expanding into higher-complexity, higher-value specialties, which is a key growth driver. Successful execution could boost subscriber growth and revenue, showcasing the potential for DTC health platforms to innovate beyond traditional offerings. | Ticker | theme_composer | HIMS | 1 | 2.52 | 1.18 | 1.0 | | 1.0 | 297.36 | 2026-11-07 | False | 1 | 0.001 | 0.12 | theme_composer | Theme composer | | |
| FDA provides perspective on explicit rule-making for peptides, specifically TB-500 and BPC-157, following the comment period. | in the next couple of weeks | 2026-11-10 | 2026-11-24 | Regulatory clarity is essential for Hims & Hers to launch these specific peptides, which could significantly expand their peptide offering and market opportunity, aligning with the broader GLP-1 theme. | Theme | | | | | | | | | | | | | | | earnings_transcript | HIMS (ticker) | HIMS_18421c70 | 2026-11-09 |
| Hims & Hers launches its Peptides+ offering, including sermorelin, glutathione, and NAD+, with clinician-led treatment plans and access to regular blood testing. | later this month | 2026-11-01 | 2026-11-30 | This expands the platform into a new, complex care category, leveraging their infrastructure and potentially driving new revenue streams and customer engagement in the longevity and wellness space. | Ticker | | | | | | | | | | | | | | | earnings_transcript | HIMS (ticker) | HIMS_7869cc52 | 2026-11-09 |
| Hims & Hers will launch flexible multi-month subscriptions across its weight loss assortment and expand access to Lilly's GLP-1 medications, Zepbound and Foundayo. | ahead of the new year | 2026-10-01 | 2026-12-31 | This broadens treatment options and improves pricing flexibility, potentially increasing customer acquisition, retention, and market share in the high-growth metabolic health category. | Ticker | | | | | | | | | | | | | | | earnings_transcript | HIMS (ticker) | HIMS_d8f2182b | 2026-11-09 |
| Hims & Hers anticipates its AI-native experience will reach nearly 100% of weight loss subscribers. | before the end of the year | 2026-10-01 | 2026-12-31 | This is expected to drive higher engagement, better adherence, and improved customer satisfaction, leading to stronger retention and potentially lower churn. | Ticker | | | | | | | | | | | | | | | earnings_transcript | HIMS (ticker) | HIMS_aa060124 | 2026-11-09 |
| Hims & Hers provides Q4 2026 guidance and updates on international profitability. Investors will be watching for continued strong international revenue growth and progress towards breakeven adjusted EBITDA in these new markets. | Q1 2027 Earnings Call | 2027-02-01 | 2027-03-15 | International expansion is a key growth lever for Hims & Hers, and its success demonstrates the scalability of the DTC health model globally. Achieving profitability in international segments would validate the investment strategy and reduce the drag on overall company margins, potentially influencing other DTC brands considering global expansion. | Theme | theme_composer | HIMS | 1 | 3.36 | 1.18 | 1.0 | Economic | 1.25 | 495.6 | 2026-11-07 | False | 1 | 0.0012 | 0.1816 | theme_composer | Theme composer | | |
| Management target for the collective international business (inclusive of Eucalyptus) to reach break-even on an adjusted EBITDA basis within 12–18 months. | within 12 to 18 months | 2027-02-23 | 2027-08-23 | Achievement would validate international scaling playbook, reduce consolidated margin drag and accelerate path to 2030 EBITDA targets; failure to reach break-even would prolong international margin pressure and may require additional investment or slower expansion. | Ticker | | | | | | | | | | | | | | | earnings_transcript | HIMS (ticker) | HIMS_8ce0db05 | 2026-02-23 |